Basel, 21 July 2022 Group sales up 5%1 at constant exchange rates (CER) and 5% in Swiss francsPharmaceuticals Division sales increase 3%; continued strong demand for new medicines to treat severe
Elecsys HCV Duo is the first commercially available immunoassay that allows the simultaneous and independent determination of the hepatitis C virus (HCV) antigen and antibody status.The Elecsys HCV Duo
In the TENAYA and LUCERNE studies, more than 60% of Vabysmo patients could be treated every four months at two years. This represents an increase from 45% at year one Patients treated with Vabysmo received
Greatest benefit continued to be seen in people who are at a high risk of recurrence (those with lymph node-positive disease)With longer follow-up, treatment effect continues to be seen regardless of hormone
The "Europe Organ Transplant Diagnostics Market 2021-2031 by Offering, Transplant, Application, Technology, End User, and Country: Trend Forecast and Growth Opportunity" report has been added to ResearchAndMarkets.com's